Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Instagram Outage Disrupts Thousands of U.S. Users 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
ALPHARETTA, Ga., Aug. 08, 2017 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced today that it will participate in three upcoming events.
Clearside will host a Key Opinion Leader (“KOL”) luncheon event on Thursday, August 10, 2017 in Boston, MA. The invited speaker for this event is Dr. David M. Brown, a prominent Houston, TX-based retinal specialist and thought leader on the research and treatment of retinal vein occlusion (“RVO”), diabetic macular edema (“DME”) and age-related macular degeneration (“AMD”). The KOL lunch event will not be webcast.
Clearside’s Chief Executive Officer and President, Daniel H. White, will participate in a panel discussion on retinal drug delivery at the Ophthalmology Innovation Summit (“OIS”) to be held Thursday, August 10, 2017 in conjunction with the 35th Annual Scientific Meeting of the American Society of Retinal Specialists (“ASRS”) in Boston, MA. The panel discussion at OIS@ASRS will not be webcast.
Clearside management will also participate in the 2017 Wedbush PacGrow Healthcare Conference on Tuesday, August 15, 2017 at the Le Parker Meridien Hotel in New York, NY. Mr. White will participate in a lunch panel entitled, “New Technologies in Drug Delivery,” at 11:30 a.m. ET and will present at 2:30 p.m. ET. A live webcast of the presentation can be accessed on Clearside’s website at www.clearsidebio.com under the “Events & Presentations” tab in the “Investor Relations” section. Following the conference, the presentation webcast will be archived on the website for 30 days.
About Clearside
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a late-stage clinical ophthalmic biopharmaceutical company that envisions a world without blindness. Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and preclinical product candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This offers potentially meaningful treatment benefit to patients suffering from sight threatening diseases like uveitis, RVO, DME and AMD. To learn more about how Clearside is changing ophthalmology, please visit us at www.clearsidebio.com.
Contacts: Stephen Kilmer Investor Relations (678) 270-3631 [email protected] Charles Deignan Chief Financial Officer (678) 270-4005 [email protected]
